Document is current

Article History

Received: 14 July 2022

Accepted: 4 January 2023

First Online: 18 February 2023

Declarations

:

: PRIMM-UK (NCT03643289) received ethical approval from the South-Central Berkshire committee of the Research Ethics Services (RES) of the NHS. PRIMM-NL (COLIPI: METc number 2012/085, NCT02600143; POINTING: METc number 2018/350, NCT04193956; and OncoLifeS: METc number 2010/109) have been approved by the Medical Ethical Committee (in Dutch: Medisch Ethische Toetsingsingscommissie or METc) of the University Medical Center Groningen (UMCG) in the Netherlands. OncoLifeS information is available on the Netherlands Trial Register at ExternalRef removed. The University of Leeds Research Ethics Committee (Ref) Number: 15/NW/0933. Written informed consent was obtained from all patients. All methods were performed in accordance with the relevant guidelines and regulations.

: Not applicable.

: RKW acted as a consultant for Takeda, received unrestricted research grants from Takeda, Johnson & Johnson, Tramedico and Ferring, and received speaker fees from MSD, Abbvie and Janssen Pharmaceuticals. EGEdV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi (paid to University Medical Center Groningen), and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, CytomX Therapeutics, Cresendo, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier and Synthon (paid to University Medical Center Groningen). JJS has acted as a consultant for Immunocore, MSD, BMS and Delcath, received honoraria from Immunocore, MSD, BMS, Delcath and Pierre Fabre, and received institutional grant funding from Immunocore, AstraZeneca and BMS. GAPH consultancy/advisory relationships and payment to the Institution with Bristol-Myers Squibb, Roche, MSD, Pfizer, Novartis, Sanofi, Pierre Fabry, Amgen and has received research grants with payments to the Institution from Bristol-Myers Squibb, Seerave. TDS is a consultant for ZOE Global. MF reports research funding from Sanofi for the identification of multi-disease drug targets through systems-immunology dissection of immune ageing. GL declares that he is a founder and owner of Genos Ltd, which offers commercial service of glycomic analysis and has several patents in this field. MH, HD, ITA are employees of Genos Ltd. HMS has acted as a consultant for Immunocore, MSD, BMS, Regeneron, Sanofi and Novartis, received honoraria from MSD, BMS, Regeneron, Sanofi and Novartis, and received institutional grant funding from Immunocore, Novartis, MSD and BMS. The other authors have nothing to disclose.